Search clinical trials for: Ofatumumab

Total 187 results

GlaxoSmithKline

Completed

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)

Multiple Sclerosis

United States, Bulgaria, Russian Federation, Spain, Germany, Czechia, Netherlands, Norway, Italy, Canada, Denmark
GlaxoSmithKline

Completed

Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients (OMS115102)

Multiple Sclerosis
GlaxoSmithKline

Terminated

Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403

Arthritis, Rheumatoid

United States, Denmark, Hungary, United Kingdom, Poland
GlaxoSmithKline

Completed

Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular

Japan
Novartis Pharmaceuticals

Completed

A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis

Multiple Sclerosis

United States
Fondazione Italiana Linfomi ONLUS

Completed

"MIRO" Molecularly Oriented Immuno-radio-therapy (FIL_MIRO)

Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3A

Italy
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Lymphoma

United States
GlaxoSmithKline

Completed

HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab

Leukaemia, Lymphocytic, Chronic
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

Leukemia, Lymphoblastic, Chronic

Italy
Massachusetts General Hospital
GlaxoSmithKline; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical...

Completed

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States
Chao Ji

Completed

Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris

Pemphigus | Pemphigus Vulgaris (PV)

China
Michael John Robertson
Novartis

Completed

Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma

Non-Hodgkin's Lymphoma

United States
Novartis Pharmaceuticals

Recruiting

Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France (SEPROS)

Multiple Sclerosis (MS)

France
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE™)

Relapsed or Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Austria, Belgium, France, Ireland, Italy, Poland, Spain, United Kingdom
Pharmacyclics LLC.
Ohio State University

Completed

Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL (PCYC-1109-CA)

B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Richter's Transformation | Prolymphocyctic Leukemia

United States
University Health Network, Toronto
Novartis

Completed

An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL)

Canada
Novartis Pharmaceuticals

Completed

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

Multiple Sclerosis

United States, Austria, Spain, Czechia, Estonia, Bulgaria, Latvia, Lithuania, Russian Federation
Joseph Tuscano
GlaxoSmithKline

Completed

Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia

United States
GlaxoSmithKline

Completed

A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic

Korea, Republic of, Japan
Novartis Pharmaceuticals

Active, not recruiting

Characterizing the Use of Ofatumumab in a Real World Setting (EAFToS)

Relapsing Multiple Sclerosis

Australia
GlaxoSmithKline

Terminated

Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy

Arthritis, Rheumatoid

Poland, Russian Federation, Argentina, Belgium, Peru, Spain, Australia, Czechia, South Africa, Chile, Hungary, United Kingdom, Romania
GlaxoSmithKline

Completed

Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Lymphoma, Large-Cell, Diffuse
Novartis Pharmaceuticals

Recruiting

A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice (CRONOS-MS)

Relapsing Forms of Multiple Sclerosis

Spain
Brown University
The Miriam Hospital; Dartmouth-Hitchcock Medical Center; Rhode Island Hospital; Memorial Hospital of Rhode Island

Terminated

Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab

Lymphoma, Non-Hodgkins

United States
GlaxoSmithKline

Completed

Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients

Arthritis, Rheumatoid

Russian Federation, Australia, Belgium, Spain, United States, New Zealand, Italy, Poland, France
Novartis Pharmaceuticals

Recruiting

WOE of Anti-CD20 Therapies

Multiple Sclerosis

United States
Januario Castro, M.D.
GlaxoSmithKline

Completed

Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) (CRC027)

CLL

United States
Nevada Cancer Institute
GlaxoSmithKline; Cephalon

Withdrawn

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Chronic Lymphocytic Leukemia (CLL)

United States
H. Lee Moffitt Cancer Center and Research Institute

Completed

Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease

United States
University of Cologne

Completed

Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

Relapsed NLPHL

Germany
GlaxoSmithKline

Completed

Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

Lymphoma, Large-Cell, Diffuse

United Kingdom
Novartis Pharmaceuticals

Completed

Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma

Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); GlaxoSmithKline

Terminated

Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

Waldenström Macroglobulinemia

United States
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Completed

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

Mantle Cell Lymphoma

United States
Novartis Pharmaceuticals

Active, not recruiting

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. (AGNOS)

Relapse Remitting Multiple Sclerosis

United States, Puerto Rico
M.D. Anderson Cancer Center
GlaxoSmithKline

Completed

Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia

United States
Grupo Español de Linfomas y Transplante Autólogo...

Completed

Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients

B-Cell Lymphomas

Spain
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Grupo Español de Linfomas y Transplante Autólogo...

Completed

Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma

Hodgkin Disease

Spain
Oncology Specialists, S.C.
University of Illinois at Chicago

Terminated

Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas

Non-Hodgkin Lymphomas

United States
GlaxoSmithKline

Completed

Phase IV Observational Study in Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic
GlaxoSmithKline

Completed

Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients (BIFROST)

Leukaemia, Lymphocytic, Chronic

United States, United Kingdom
M.D. Anderson Cancer Center
GlaxoSmithKline

Terminated

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

Lymphoma | Leukemia

United States
SCRI Development Innovations, LLC
GlaxoSmithKline; Novartis

Completed

Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
GlaxoSmithKline

Completed

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

Waldenstrom Macroglobulinaemia

United States
Nevada Cancer Institute
GlaxoSmithKline; Cephalon

Terminated

Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

Chronic Lymphocytic Leukemia (CLL)

United States
Novartis Pharmaceuticals

Completed

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

Relapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple Sclerosis

Japan
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

Pemphigus Vulgaris

United States, Australia, Greece, Israel, Italy, Japan, Poland, Romania
GlaxoSmithKline

Completed

Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects

Leukaemia, Lymphocytic, Chronic

Australia, United States, New Zealand
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Relapsing Multiple Sclerosis

Japan, Russian Federation

Search clinical trials for: Ofatumumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations